Nanobiotix's Nanoprimer Shows Improved Bioavailability, Reduced Toxicity for LNP-DNA Immunotherapy in Preclinical Data
Summary
Nanobiotix announced new preclinical data at the American Association for Cancer Research (AACR) meeting, demonstrating that its Nanoprimer technology significantly improved systemic bioavailability and reduced hepatic toxicity for LNP-delivered DNA immunotherapy. The data suggests the Nanoprimer can mitigate rapid hepatic clearance and inflammatory responses, which are common limitations for LNP-DNA therapies. This positive preclinical validation supports the potential of Nanobiotix's early-stage platform to enhance the efficacy and safety of advanced therapeutics, bolstering its internal pipeline and potential for external collaborations. Investors will be watching for further progression of the Nanoprimer into clinical stages or new partnership announcements.
At the time of this announcement, NBTX was trading at $33.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $3.12 to $41.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.